IGC Pharma plans to present its artificial-intelligence portfolio for Alzheimer's research at the AAIC 2026 conference, the company announced in a release distributed by outlets including Yahoo Finance and covered via Google News and Bing News.
The centerpiece is a system the company calls the AHA Platform. According to the announcement, the platform cut the time needed to harmonize Alzheimer's data by 90% in what IGC describes as a representative workflow. Data harmonization is the often-tedious work of taking information collected in different formats, from different studies or hospitals, and reshaping it so it can be analyzed together. Speeding that step up can shorten the runway before researchers ever reach the science itself.
IGC Pharma says it will give seven presentations at the conference. Per the company, they cover patent-pending agentic automation, speech-based cognitive models, mining of electronic health records (EHR), and predictive analytics. Taken together, IGC frames these tools as support for both Alzheimer's drug discovery and clinical development.
A few caveats are worth keeping in mind. The 90% figure comes from IGC's own announcement and is tied to a "representative workflow" rather than an independently audited, real-world deployment. The sources describe presentations and platforms, not peer-reviewed results or regulatory approvals.
Why it matters: Alzheimer's research generates enormous, messy datasets, and much of the effort goes into simply making that data usable, so tools that promise to automate the grunt work could help researchers spend more time on discovery, though the claims here come from the company and remain to be independently proven.